Oculis Holding AG
OCS
Company Profile
Business description
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
Contact
Bahnhofstrasse 20
Zug6300
CHET: +41 417119325
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
49
Stocks News & Analysis
stocks
Finding value in the Aussie mining sector
Is the mining sector overvalued? A new Morningstar report highlights pockets of value that remain.
stocks
Strong start to the year for cheap ASX share
Investors are ignoring a strong long-term outlook.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,800.40 | 36.00 | 0.41% |
| CAC 40 | 7,982.84 | 0.19 | 0.00% |
| DAX 40 | 23,246.25 | 154.38 | 0.67% |
| Dow JONES (US) | 46,252.76 | 7.35 | 0.02% |
| FTSE 100 | 9,546.67 | 6.96 | 0.07% |
| HKSE | 25,716.50 | 496.48 | 1.97% |
| NASDAQ | 22,603.39 | 330.31 | 1.48% |
| Nikkei 225 | 48,625.88 | 1,198.06 | -2.40% |
| NZX 50 Index | 13,499.85 | 80.45 | 0.60% |
| S&P 500 | 6,649.28 | 46.29 | 0.70% |
| S&P/ASX 200 | 8,525.10 | 33.40 | 0.39% |
| SSE Composite Index | 3,836.77 | 1.87 | 0.05% |